Satya Bio is a biotech intelligence platform purpose-built for buy-side healthcare investors and pharma business development teams. We consolidate competitive landscapes, catalyst timelines, pipeline data, and deal intelligence across millions of data points — turning hours of manual research into structured, decision-ready analysis.
Satya Bio is built for two audiences that need the same competitive data but use it differently.
Hedge fund analysts, portfolio managers, and buy-side teams tracking biotech catalysts, pipeline shifts, and M&A signals across their coverage universe. PDUFA dates, Phase 3 readouts, and competitive positioning updated daily — so you’re never caught off guard by a data readout or deal announcement.
Business development professionals evaluating competitive landscapes before pursuing inbound or outbound deals. See every asset in a target class, who owns it, what clinical stage it’s at, and what comparable deals have closed for — all in one view. No more assembling landscapes from scratch for every BD committee meeting.
Unlike legacy platforms that bury you in raw data, Satya Bio delivers curated, analyst-grade intelligence you can act on immediately — whether you’re building a board deck, preparing for a BD committee, or sizing an investment.
Deep-dive competitive landscape reports across high-value therapeutic targets. Side-by-side clinical data comparison, mechanism analysis, and competitive positioning for every asset in the space.
Upcoming PDUFA dates, Phase 3 readouts, regulatory milestones, and conference presentations across your coverage universe. Automated alerts so nothing slips through.
Biotech deal value tracked with terms, structure, upfront payments, milestones, and strategic context. Understand deal comps and valuations across therapeutic areas.
Thousands of assets tracked with clinical stage, mechanism of action, trial design, and competitive positioning. Pipeline-level comparison across companies and targets.
Key Opinion Leader identification via PubMed publication analysis. Find the most influential researchers and clinicians by target, therapeutic area, or disease indication.
Institutional ownership changes, 13F filings, insider transactions, and proxy filings across your biotech coverage universe. Spot ownership signals before the market moves.
We build and maintain competitive landscapes across the highest-activity areas in biotech — from specific molecular targets to broader platform modalities. Each landscape maps every relevant asset, company, clinical stage, and deal in the space.
Every data point on Satya Bio is sourced from primary regulatory and corporate filings — not scraped summaries or third-party aggregators. We verify and cross-reference across sources to ensure accuracy.
Original analysis on competitive landscapes, biotech deal activity, and catalyst events. Written for investment professionals and pharma BD teams who need depth, not headlines.
Competitive landscape deep dives — every asset in a target class, by stage and mechanism. Example: “The Obesity Drug Landscape: Beyond GLP-1, What’s Next”
Deal breakdowns and valuation analysis — what recent M&A and licensing deals signal about target valuations and competitive dynamics
Weekly catalyst previews — upcoming PDUFA dates, Phase 3 readouts, and regulatory milestones across the biotech universe
Analytical frameworks for evaluating clinical data, assessing biotech deal comps, and sizing investment opportunities in competitive target classes
Satya Bio offers a sample of our competitive intelligence for free. Full access unlocks the complete platform — every company profile, target landscape, catalyst alert, and deal breakdown.
Currently onboarding select funds and pharma BD teams.
Get Started